Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $1,128,933.28 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 124,882 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $1,128,933.28. Following the completion of the transaction, the insider directly owned 3,033,078 shares in the company, valued at $27,419,025.12. The trade was a 3.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $7.03 on Friday. The company’s 50 day simple moving average is $10.89 and its 200-day simple moving average is $11.71. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39. Ocular Therapeutix, Inc. has a 1 year low of $5.78 and a 1 year high of $16.44. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -4.88 and a beta of 0.90.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The firm’s quarterly revenue was down 22.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.29) EPS. As a group, equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on OCUL shares. Needham & Company LLC restated a “buy” rating and set a $20.00 target price on shares of Ocular Therapeutix in a report on Monday, December 8th. TD Cowen reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Thursday, October 30th. Citigroup reiterated an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday. Jefferies Financial Group reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, January 22nd. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OCUL. Steward Partners Investment Advisory LLC lifted its stake in Ocular Therapeutix by 124.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,242 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,392 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Ocular Therapeutix during the fourth quarter worth approximately $42,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $61,000. Finally, KBC Group NV acquired a new position in shares of Ocular Therapeutix in the 4th quarter valued at $78,000. 59.21% of the stock is owned by institutional investors and hedge funds.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.